Blauvelt, Andrew, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, and Subhashis Banerjee. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s49. Accessed December 8, 2023.